PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Hansa Biopharma appoints new Chief Executive Officer

Lund, Sweden, 24 April 2025Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company.

“On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure. Under his guidance, Hansa has evolved from a clinical-stage company into a commercial-stage biopharmaceutical organization, navigating both transformative progress and substantial challenges. We deeply appreciate Søren’s commitment to the Company and wish him every success in his future endeavors,” said Peter Nicklin, Chairman of the Board, Hansa Biopharma.  “With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the Company’s strategic positioning.  The Board is confident that she is the right person to successfully lead Hansa through this next chapter, and we look forward to working closely with her.”

Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company successfully launched and commercialized the first ever approved drug for immunog…

Read More...
Hansa Biopharma appoints new Chief Executive Officer

Articles